Biotech · Private company
OX2 Therapeutics
Track this companyFree. Adds OX2 Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials21 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline2
- Treatment with CD200AR-LPhase 1 · Diffuse Midline Glioma, H3 K27M-MutantClinicalTrials.gov · fetched Nov 12, 2026
- Treatment with hP1A8Phase 1 · GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young AdultsPHASE1 · RECRUITING · started Mar 15, 2024ClinicalTrials.gov NCT06305910 · fetched Nov 12, 2026
- Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent GlioblastomaPHASE1 · UNKNOWN · started Dec 1, 2020ClinicalTrials.gov NCT04642937 · fetched Nov 12, 2026